Cancer-focused Abdera Therapeutics collects $142m for Series A, B deals

Versant Ventures and Amplitude Ventures led the Series A round, while venBio Partners led the Series B round.

20 April 2023•2 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.